Table 2 Distribution of specific tumour characteristics among CES tertiles.

From: Centromere and kinetochore gene misexpression predicts cancer patient survival and response to radiotherapy and chemotherapy

Clinical factors

CES tertile

χ2-test

 

Low (%)

Intermediate (%)

High (%)

(P value)

Breast cancer

    

Grade 3*

12

23

65

5E−36

ER negative†

8

19

73

3E−23

Positive lymph node†

34

35

31

0.682

High stage (III+IV)†

33

35

32

0.899

NSCLC (ADC and SCC)

    

Positive lymph node‡

24

40

36

0.047

High stage (III+IV)‡

26

37

37

0.161

SCC versus ADC§

9

31

60

1E−14

  1. ADC, adenocarcinoma; CES, Centromere and kinetochore gene Expression Score; NSCLC, non-small cell lung cancer; SCC, squamous cell carcinoma
  2. Percentages of tumours with specific tumour characteristics among CES tertiles were displayed. Significant P values determined by χ2-test are bolded (P<0.05).
  3. *Five data sets with grade information listed in Supplementary Table 12 were pooled (GSE6532, GSE1456, GSE3494, NKI and Gray data set).
  4. †TCGA breast adenocarcinoma data set with 0.3 tumour purity cutoff. Tumour purity cutoff at 0.7 results in similar conclusions but not shown.
  5. ‡TCGA lung ADC and SCC data sets were pooled. Only lung SCC data set contains lymph node invasion information.
  6. §Three NSCLC data sets containing histological subtype information listed in Supplementary Table 13 were pooled (GSE14814, GSE42127 and GSE37745).
Back to article page